We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
In this review of 9 randomized controlled trials, the long-term (>12 months) recurrence rates of actinic keratoses (AKs) were assessed. Cryotherapy and photodynamic therapy (PDT) with 5-aminolevulinate (ALA) demonstrated the lowest recurrence rate of 39%. These were followed by placebo (44%), PDT with methyl-aminolevulinate (MAL, 45%), and imiquimod (45%). The highest recurrence rates were observed in 5-fluorouracil (52%), ablative laser treatment (54%), and diclofenac (85%). In clinical trials evaluating lesion-specific recurrence rates, placebo had the lower recurrence rate (15%), followed by ALA-PDT (20%) and MAL-PDT (34%).
The long-term recurrence rates of AKs are high, even after initial clearance. The majority of patients treated for AKs will require regular surveillance and retreatment.
Actinic keratoses (AK) are common lesions in light-skinned individuals, which can progress to invasive cutaneous squamous cell carcinoma.1 Most treatment options are superior to placebo regarding lesion clearance.2 The majority of studies focus on short-term clearance evaluated within 3-6 months after treatment although AK are considered a chronic condition.2, 3 Here, we systematically investigated the recurrence rates of AK reported from parallel-arm randomized controlled trials (RCT).